Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axsome Therapeutics (AXSM) Other Gross PP&E Adjustments (2021 - 2026)

Axsome Therapeutics' Other Gross PP&E Adjustments history spans 6 years, with the latest figure at -$24.8 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 13.54% to -$24.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$24.8 million, a 13.54% increase, with the full-year FY2025 number at -$20.9 million, down 287.48% from a year prior.
  • Other Gross PP&E Adjustments hit -$24.8 million in Q1 2026 for Axsome Therapeutics, down from -$20.9 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for AXSM hit a ceiling of -$384568.0 in Q3 2022 and a floor of -$28.7 million in Q1 2025.
  • Historically, Other Gross PP&E Adjustments has averaged -$11.3 million across 5 years, with a median of -$8.7 million in 2023.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 36.38% in 2022 and later plummeted 2155.78% in 2023.
  • Tracing AXSM's Other Gross PP&E Adjustments over 5 years: stood at -$420000.0 in 2022, then plummeted by 1512.38% to -$6.8 million in 2023, then increased by 20.51% to -$5.4 million in 2024, then tumbled by 287.48% to -$20.9 million in 2025, then fell by 18.98% to -$24.8 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for AXSM at -$24.8 million in Q1 2026, -$20.9 million in Q4 2025, and -$23.3 million in Q3 2025.